Want to join the conversation?
$CAT 2Q15 PR: FY15 Outlook: Sales and revenues of $49Bil compared with previous outlook of $50Bil. Profit per share of $4.70, or $5.00 per share excluding restructuring costs of about $250MM, remains unchanged. CAT expects ME&T CapEx to be same as 2014 CapEx of $1.6Bil.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.